tetano
Editor, Senior Moderator
Acta Paediatr
. 2022 Dec 30.
doi: 10.1111/apa.16652. Online ahead of print.
The safety of COVID-19 vaccination in immunocompromised children and young adults with immune-mediated inflammatory disease
Benjamin Sahn[SUP] #[/SUP][SUP] 1 2 [/SUP], Ying Lu[SUP] #[/SUP][SUP] 1 2 [/SUP], Joyce S Hui-Yuen[SUP] 1 3 [/SUP], Joanna Fishbein[SUP] 4 [/SUP], Beth S Gottlieb[SUP] 1 3 [/SUP], Barbara A Eberhard[SUP] 1 3 [/SUP], Heather M Walters[SUP] 1 3 [/SUP]
Affiliations
Abstract
Aim: To assess safety of COVID-19 vaccination in pediatric patients with immune-mediated inflammatory disease (IMID) METHODS: Subjects 5-21 years of age with IMID who received at least one COVID-19 vaccine completed electronic surveys after each vaccine to assess side effects within one week of vaccination, current medications, and COVID-19 testing after vaccination. Charts were reviewed for COVID-19 polymerase chain reaction and IgG response to SARS-CoV-2 spike protein results, and for disease flare during the study period.
Results: Among 190 enrolled subjects, 71% were female, with median age 17 (range 6-21) years. The most common diagnosis was juvenile idiopathic arthritis/rheumatoid arthritis (55%). 78% of subjects were taking immunosuppressive medication. At least one side effect was reported in 65% of subjects after any dose of the vaccine; with side effects in 38%, 53%, and 55% of subjects after the first, second, and third vaccine doses, respectively. The most common side effects were injection site pain (59%), fatigue (54%), and headache (39%). No anaphylaxis or myocarditis was reported. Three subjects (2%) experienced disease flare.
Conclusion: In our cohort of pediatric patients with IMID, observed side effects were found to be mild and disease flare rates were found to be low following COVID-19 vaccination.
Keywords: autoimmune disease; coronavirus; immunosuppressive therapy; vaccination.
. 2022 Dec 30.
doi: 10.1111/apa.16652. Online ahead of print.
The safety of COVID-19 vaccination in immunocompromised children and young adults with immune-mediated inflammatory disease
Benjamin Sahn[SUP] #[/SUP][SUP] 1 2 [/SUP], Ying Lu[SUP] #[/SUP][SUP] 1 2 [/SUP], Joyce S Hui-Yuen[SUP] 1 3 [/SUP], Joanna Fishbein[SUP] 4 [/SUP], Beth S Gottlieb[SUP] 1 3 [/SUP], Barbara A Eberhard[SUP] 1 3 [/SUP], Heather M Walters[SUP] 1 3 [/SUP]
Affiliations
- PMID: 36583590
- DOI: 10.1111/apa.16652
Abstract
Aim: To assess safety of COVID-19 vaccination in pediatric patients with immune-mediated inflammatory disease (IMID) METHODS: Subjects 5-21 years of age with IMID who received at least one COVID-19 vaccine completed electronic surveys after each vaccine to assess side effects within one week of vaccination, current medications, and COVID-19 testing after vaccination. Charts were reviewed for COVID-19 polymerase chain reaction and IgG response to SARS-CoV-2 spike protein results, and for disease flare during the study period.
Results: Among 190 enrolled subjects, 71% were female, with median age 17 (range 6-21) years. The most common diagnosis was juvenile idiopathic arthritis/rheumatoid arthritis (55%). 78% of subjects were taking immunosuppressive medication. At least one side effect was reported in 65% of subjects after any dose of the vaccine; with side effects in 38%, 53%, and 55% of subjects after the first, second, and third vaccine doses, respectively. The most common side effects were injection site pain (59%), fatigue (54%), and headache (39%). No anaphylaxis or myocarditis was reported. Three subjects (2%) experienced disease flare.
Conclusion: In our cohort of pediatric patients with IMID, observed side effects were found to be mild and disease flare rates were found to be low following COVID-19 vaccination.
Keywords: autoimmune disease; coronavirus; immunosuppressive therapy; vaccination.